Concourse Financial Group Securities, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 22 shares of SUPN stock, worth $794. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22
Previous 25
12.0%
Holding current value
$794
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$375 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$221 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$184 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$104 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$95 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.93B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...